ArticleCurrent oncology (Toronto, Ont.)2022

Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort.

Amanda J W Gibson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.